An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy https://t.co/1UqDlhxRqi https://t.co/dRR5tJrSyx

New Research: An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy: Background This study aimed to develop a vaccine that targets mutation-derived neoantigen in Chinese… https://t.co/I